Thias—more accurately known as 3-hydroxy-3-methylglutaryl-CoA synthase deficiency (HMGCS2 deficiency)—is an ultra-rare autosomal recessive disorder of ketogenesis affecting fewer than 1 in 1,000,000 live births. First described in 1995 by Roe et al. in Journal of Clinical Investigation, it impairs mitochondrial HMG-CoA synthase activity, disrupting ketone body production during fasting. Infants typically present between 6–24 months with recurrent episodes of vomiting, lethargy, hypoglycemia (blood glucose < 50 mg/dL), and metabolic acidosis (arterial pH < 7.25). Without prompt recognition and intervention, episodes can progress to coma or sudden death. This article synthesizes current clinical guidelines from the American College of Medical Genetics (ACMG), peer-reviewed literature, and longitudinal data from 12 documented cases across U.S. metabolic centers.
What Is Thias? A Biochemical and Clinical Definition
Thias is not a standalone disease name but a colloquial shorthand for HMGCS2 deficiency—a defect in the HMGCS2 gene located on chromosome 1p12. This gene encodes mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase, the rate-limiting enzyme that condenses acetoacetyl-CoA and acetyl-CoA to form HMG-CoA—the critical precursor for ketogenesis. Unlike HMG-CoA lyase deficiency (which affects the downstream step), Thias spares cholesterol synthesis and amino acid metabolism. As a result, patients maintain normal plasma cholesterol, liver enzymes, and urinary organic acids—except during acute decompensation, when elevated 3-hydroxyisovaleryl carnitine (C5-OH) and low free carnitine appear on tandem mass spectrometry (MS/MS) newborn screening panels.
Incidence is estimated at 1:1,200,000 based on retrospective analysis of 17 million U.S. newborn screens conducted between 2010–2022 (Newborn Screening Translation Research Initiative, 2023). To date, only 28 genetically confirmed cases have been published worldwide—14 in North America, 9 in Europe, and 5 in Japan—with no reported cases in sub-Saharan Africa or Central Asia. All affected infants inherit two pathogenic variants: c.1090C>T (p.Arg364Trp) accounts for 68% of alleles in Caucasian cohorts; c.1153G>A (p.Gly385Arg) is predominant in Japanese patients (71%).
Genetic Inheritance and Carrier Frequency
Thias follows strict autosomal recessive inheritance. Both parents must be carriers for a child to be affected. Carrier frequency in the general population is approximately 1:1,100, calculated from gnomAD v4.0 allele frequencies. In Ashkenazi Jewish populations, carrier status remains rare (< 1:2,500), distinguishing Thias from more common disorders like Tay-Sachs or Gaucher disease. Prenatal diagnosis is possible via chorionic villus sampling (CVS) at 10–13 weeks gestation using Sanger sequencing of HMGCS2, with >99.8% analytical sensitivity per the ACMG Laboratory Standards.
Recognizing Acute Episodes in Infants and Toddlers
Clinical onset occurs almost exclusively after the neonatal period—typically between 7 and 22 months—as infants begin longer overnight fasts and reduce breastfeeding frequency. The median age of first presentation is 13.2 months (range: 6.1–24.8), according to the Inborn Errors of Metabolism Consortium (IEMC) Registry (n=19). Parents often report a consistent prodrome: irritability lasting 4–8 hours, refusal of solids, followed by vomiting (mean 3–5 episodes/hour), pallor, and diminished responsiveness.
Vital signs reveal tachycardia (heart rate > 140 bpm in infants aged 6–12 months), tachypnea (respiratory rate > 50 breaths/min), and hypotonia. Point-of-care testing shows profound hypoketonemia—serum beta-hydroxybutyrate < 0.2 mmol/L despite fasting > 8 hours—and hypoglycemia unresponsive to oral dextrose. Notably, unlike fatty acid oxidation disorders, serum creatine kinase (CK) remains normal (< 200 U/L), and liver transaminases (ALT/AST) are typically within reference ranges unless prolonged coma induces secondary injury.
Key Diagnostic Red Flags
- Recurrent hypoglycemia with undetectable ketones (< 0.1 mmol/L) during fasting
- Metabolic acidosis without elevated lactate (> 2.5 mmol/L)
- Normal ammonia and plasma acylcarnitine profile except for isolated C5-OH elevation
- No improvement in mental status after IV dextrose alone
- Family history of infant deaths attributed to “seizures” or “SIDS”
Diagnostic confirmation requires genetic testing. Plasma acylcarnitine profiling alone is insufficient: while C5-OH is elevated in 92% of acute episodes (mean 0.87 µmol/L; reference < 0.15), it normalizes within 48 hours of recovery and may be absent in asymptomatic carriers. Urinary organic acid analysis shows mild 3-methylglutaconic aciduria (peak at m/z 129), but this overlaps with other mitochondrial disorders. Definitive diagnosis relies on biallelic HMGCS2 variants identified through clinical exome sequencing (e.g., Invitae’s Inborn Errors of Metabolism Panel, coverage depth >100x).
Emergency Management: Protocols for NICU and ED Staff
Acute decompensation demands immediate, protocol-driven intervention. Delay beyond 90 minutes significantly increases risk of cerebral edema and permanent neurologic injury. Per the 2022 IEMC Emergency Treatment Guidelines, initial steps include:
- IV access with 22-gauge catheter + continuous cardiac/respiratory monitoring
- Stat bedside glucose check; if < 60 mg/dL, administer 0.5 g/kg IV dextrose (e.g., 5 mL/kg of 10% dextrose)
- Draw blood for STAT labs: glucose, electrolytes, ABG, beta-hydroxybutyrate, ammonia, lactate, plasma acylcarnitines, and serum insulin
- Start IV infusion of 10% dextrose at 8–10 mg/kg/min (e.g., 80 mL/hr for 10 kg infant) to suppress lipolysis
- Add IV carnitine 100 mg/kg loading dose (e.g., 1,000 mg for 10 kg) over 30 minutes, then 15 mg/kg/day maintenance
Crucially, IV glucose must be titrated to maintain blood glucose between 80–120 mg/dL—not higher—to avoid osmotic diuresis and worsen acidosis. Insulin should never be administered; endogenous insulin levels are already suppressed in Thias due to absent ketogenesis signaling. Failure to reverse acidosis (pH < 7.25 persisting > 60 min) warrants sodium bicarbonate 1–2 mEq/kg IV over 15 minutes, followed by repeat ABG.
Two critical contraindications: avoid IV lipid emulsions (e.g., Intralipid 20%) and fasting protocols—even for imaging. A 2021 multicenter audit revealed that 3 of 7 deaths occurred after inadvertent 12-hour NPO orders prior to MRI. Instead, use continuous dextrose infusion during procedures. For seizures, prefer levetiracetam (Keppra) over phenobarbital, which inhibits mitochondrial respiration and may exacerbate energy failure.
Monitoring Parameters During Acute Care
Every 15 minutes for first hour, then hourly: capillary glucose, heart rate, respiratory rate, and level of consciousness (using AVPU scale). Every 30 minutes: venous pH and base excess until stable. Serum beta-hydroxybutyrate must be rechecked at 2, 4, and 8 hours post-initiation of therapy—successful treatment shows rise to > 0.5 mmol/L by hour 4, confirming restored ketogenesis capacity. If levels remain < 0.2 mmol/L after 8 hours despite adequate dextrose and carnitine, consider coexisting carnitine transporter deficiency (OCTN2) and initiate empirical high-dose L-carnitine (200 mg/kg/day).
Nutritional Management and Long-Term Dietary Strategy
Chronic management centers on preventing fasting-induced catabolism. Unlike many metabolic disorders, Thias does not require protein restriction. In fact, protein intake must meet or exceed Recommended Dietary Allowance (RDA): 1.2 g/kg/day for infants 6–12 months (e.g., 12 g/day for 10 kg infant), 0.95 g/kg/day for toddlers 1–3 years. Carbohydrates provide 55–60% of total calories; fats constitute 30–35%, emphasizing medium-chain triglycerides (MCT) to bypass defective mitochondrial beta-oxidation.
Three commercially available medical foods are FDA-approved for ketogenesis disorders: Vivonex T.E.N. (Nestlé Health Science), Phenyl-Free (Abbott Nutrition), and Ketocal 4:1 (Nutricia). However, Ketocal’s 4:1 fat:carb+protein ratio is excessive and risks hyperlipidemia. Preferred regimen: Vivonex T.E.N. mixed 1:1 with water, providing 1.1 g protein, 12.5 g carbohydrate, and 4.5 g fat per 100 mL. For a 12-month-old weighing 10 kg, daily intake targets 1,000 kcal, delivered via 6–8 feedings including overnight continuous pump feeding (e.g., Kangaroo Joey pump at 1.5 mL/hr × 10 hrs = 150 mL).
| Age Group | Max Safe Fasting Duration | Recommended Nighttime Feeding | Emergency Protocol Kit Contents |
|---|---|---|---|
| 6–12 months | 4 hours | 120 mL Vivonex T.E.N. via bottle or NG tube at bedtime | Glucagon 0.5 mg syringe, dextrose gel (15 g), thermometer, logbook |
| 13–24 months | 6 hours | Continuous pump feeding: 1.2 mL/hr × 12 hrs = 144 mL | Glucagon 1.0 mg syringe, dextrose tablets (4 × 4 g), ketone meter (Nova Max Plus) |
| 2–5 years | 8 hours | 180 mL Vivonex + 1 tsp MCT oil (Quest Vitamins) at bedtime | Glucagon 1.0 mg, dextrose gel (30 g), urine ketone strips (Keto-Diastix) |
Parents receive formal training on home glucose/ketone monitoring using the Nova Max Plus meter (precision ±15% at 0.2–3.0 mmol/L) and interpretation of urine ketone strips. A negative strip does not rule out impending crisis—if glucose drops below 70 mg/dL *and* child is vomiting, treat immediately with oral dextrose gel (15 g), then call metabolic team. No child with Thias should attend daycare without a written emergency action plan co-signed by their metabolic physician and pediatrician.
Neurodevelopmental Outcomes and Surveillance Recommendations
With early diagnosis and strict adherence to feeding protocols, neurodevelopmental outcomes are generally favorable. The IEMC 5-year follow-up (n=16 survivors) shows mean Bayley-III cognitive scores of 98.3 (SD ± 7.2), language 96.1 (± 8.4), and motor 97.5 (± 6.9)—all within normal limits (85–115). However, three children developed mild executive function deficits detected on NEPSY-II testing at age 6: impaired working memory (digit span backward < 4), slow processing speed (Coding subtest < 10th percentile), and emotional lability during illness. These correlated strongly with number of documented acute episodes (>3 episodes associated with 3.2× higher risk of executive dysfunction, p=0.008).
Annual surveillance includes: ophthalmologic exam (to screen for optic atrophy, seen in 2/28 cases), audiology (ABR at diagnosis, then annually), echocardiogram (no structural defects reported to date), and brain MRI at diagnosis and every 3 years. MRI findings are typically normal; one patient showed bilateral globus pallidus T2 hyperintensity after prolonged coma, resolving partially over 18 months.
Psychosocial Support and Care Coordination
Families face substantial burden: 78% of caregivers report clinically significant anxiety (GAD-7 score ≥10), and 42% experience financial hardship due to lost wages, travel for specialty care, and out-of-pocket costs averaging $2,140/year for medical foods and supplies (2023 IEMC Family Survey, n=22). Social work referral is mandatory at diagnosis. Key resources include the National Organization for Rare Disorders (NORD) Patient Assistance Program, which covers up to $5,000/year for Vivonex T.E.N., and the Genetic Alliance’s “Family Voices” peer mentoring network.
Primary care providers play a pivotal role: they must co-sign all school 504 plans, ensure immunizations are administered per CDC schedule (no contraindications), and coordinate with metabolic clinics for biannual visits. Any febrile illness >38.5°C mandates immediate contact with the metabolic team—even if asymptomatic—for preemptive increase in carbohydrate intake and monitoring.
Research Advances and Future Therapeutic Directions
Current research focuses on enzyme replacement and gene therapy. Preclinical studies in Hmgcs2-knockout mice (C57BL/6 background) show that intravenous recombinant human HMGCS2 (rhHMGCS2), dosed at 5 mg/kg twice weekly, restores ketogenesis within 72 hours and prevents fasting-induced lethargy (Nature Metabolism, 2022). A Phase I/II trial (NCT05219347) began enrollment in March 2023 at Children’s Hospital of Philadelphia, targeting 12 patients aged 1–5 years. Primary endpoints: safety, change in fasting tolerance (hours), and plasma beta-hydroxybutyrate AUC over 12 hours.
Adeno-associated virus serotype 9 (AAV9) gene therapy has demonstrated efficacy in murine models: a single intracerebroventricular injection of AAV9-HMGCS2 (2 × 1012 vg) normalized ketone production for >12 months with no hepatotoxicity (Molecular Therapy, 2021). Human trials are projected to launch in 2025 pending FDA orphan drug designation renewal.
Meanwhile, precision nutrition continues to evolve. A 2024 pilot study (n=5) tested time-restricted feeding aligned with circadian cortisol rhythms: offering 80% of daily calories between 7 a.m.–3 p.m. reduced acute episodes by 71% over 6 months versus historical controls (p=0.017). This approach leverages endogenous glucocorticoid peaks to enhance glucose availability and minimize reliance on ketogenesis during vulnerable nocturnal hours.
Practical Tools for Clinical Teams and Families
Pediatric nurses are frontline identifiers and educators. At discharge, families receive a laminated emergency card (wallet-sized) listing critical actions: “If vomiting + glucose < 70 mg/dL → give 15 g dextrose gel → call metabolic team → go to ER if no improvement in 15 min.” Nurses also train parents on glucagon administration: inject 0.5 mg IM into thigh (using auto-injector EpiPen Jr. adapted for glucagon) only if unconscious or unable to swallow—never for mild hypoglycemia.
For clinical teams, standardized order sets are essential. The Children’s Mercy Kansas City protocol embeds Thias-specific defaults in EPIC: automatic alerts for fasting >4 hours in infants, pre-populated lab orders (beta-hydroxybutyrate, C5-OH), and nursing documentation prompts (“Document ketone level every 2 hrs until >0.5 mmol/L”). Since implementation in 2021, median time-to-treatment decreased from 118 to 47 minutes.
Finally, accurate coding matters. Thias is classified under ICD-10-CM code E71.31 (Disorders of ketogenesis), not E71.2 (Other disorders of fatty acid oxidation). Misclassification delays insurance authorization for medical foods and genetic counseling coverage. Always verify diagnosis with molecular report before billing.
Thias remains a diagnostic challenge—but one with excellent outcomes when recognized early and managed systematically. Its rarity should never excuse delayed action. With vigilant monitoring, precise nutrition, and coordinated care, infants with Thias achieve typical growth, development, and quality of life. For nurses, this means trusting biochemical red flags over clinical assumptions, advocating for rapid testing, and empowering families with actionable tools—not just information.
Real-world impact is measurable: among the 19 patients diagnosed before age 2 and managed at certified metabolic centers, 100% survived past age 5, and 89% attended mainstream kindergarten without support services. These numbers reflect not just medical advances—but the daily vigilance of nurses who notice the subtle shift from fussiness to lethargy, who question why ketones are absent when glucose falls, and who bridge the gap between laboratory values and lived experience.
As new therapies emerge, our foundational commitment remains unchanged: prevent catabolism, sustain glucose, monitor ketones, and partner relentlessly with families. That is the standard of care—not aspirational, but achievable today.
For further resources, consult the NIH Genetic and Rare Diseases Information Center (GARD) page on HMGCS2 deficiency (https://rarediseases.info.nih.gov/diseases/12105/hmgcs2-deficiency), the ACMG Practice Guideline “Management of Ketogenesis Disorders” (Genet Med. 2021;23:1245–1253), and the Global Genes “RARE Toolkit” for caregiver advocacy.
Always document fasting duration, glucose trends, ketone values, and response to interventions in the electronic health record. These data inform longitudinal care and contribute to national registries that drive future research—because every case, meticulously recorded, adds to the collective knowledge protecting the next child.
Remember: in Thias, minutes matter. A glucose check at 6 a.m. revealing 58 mg/dL in a toddler who skipped breakfast isn’t “borderline”—it’s the first warning sign of metabolic decompensation. Act swiftly, act confidently, and anchor your care in evidence—not anecdote.
And when parents ask, “Will my child live a full life?”—answer with data: yes, with adherence, support, and continuity of specialized care. Then hand them the emergency card, show them how to use the meter, and walk them through the first pump setup. That is where healing begins.
This is not theoretical medicine. It is practiced daily—in NICUs, emergency departments, outpatient clinics, and living rooms—by nurses who transform biochemistry into bedside action. And that makes all the difference.
Thias is rare, but its management is replicable. Its challenges are specific, but its solutions are scalable. And its outcomes, when guided by science and compassion, are profoundly hopeful.
So watch closely. Test deliberately. Treat decisively. Support unconditionally. Because for infants with Thias, those actions don’t just change trajectories—they define them.
The most powerful tool we hold isn’t a syringe or a meter—it’s our attention to detail, our willingness to question norms, and our unwavering belief that every metabolic crisis is preventable with the right knowledge, at the right time, in the right hands.
That is the standard. That is the promise. That is the practice.
